09/786 009

C9C

Practitioner's Docket No. NEB-150-PUS *PATENT*

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Patent Number: 7,001,745
Issued: February 21, 2006
Name of Patentee: Ming-qun Xu

Title of Invention: Intein-Mediated Peptide Ligation

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

REQUEST FOR CERTIFICATE OF CORRECTION OF PATENT FOR PTO MISTAKE (37 C.F.R. § 1.322(a))

1. Attached is PTO/SB/44 (also Form PTO-1050) in a form suitable for printing.

2. The abstract printed in the above-referenced patent is an abstract completely unrelated to the subject case and not belonging in the file. It is an abstract of patent numbers 6,500,798 and 6,939,847, both of which are assigned to the Board of Regents, The University of Texas System. The abstract that should have been printed with the above-referenced patent is the abstract of its parent PCT case, namely, PCT/US99/22776 filed September 30, 1999 and published on April 6, 2000 as PCT publication No. WO00/018881.

3. Please send the Certificate to:

Name: Harriet M. Strimpel, D.Phil.
Address: New England Biolabs, Inc.
240 County Road
Ipswich, MA 01938

Assignee: New England Biolabs, Inc.

New England Biolabs, Inc.
Assignee
Harriet M. Strimpel, D.Phil., Chief Patent Counsel

Assignment recorded on February 28, 2001
Reel 011618
Frame 0819

PTO/SB/44 (04-05)
Approved for use through 04/30/2007. OMB 0651-0033
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

(Also Form PTO-1050)

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. :7,001,745

APPLICATION NO.: 09/786,009

ISSUE DATE :February 21, 2006

INVENTOR(S) : Ming-qun Xu, et al.

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

On title page, item 57 Abstract

replace

(57) **ABSTRACT**

The present invention provides methods that utilize compositions containing colostrinin, an constituent peptide thereof, an active analog thereof, and combinations thereof, as an oxidative stress regulator.

with

(57) Abstract: An in vitro method for producing a semi-synthetic fusion protein is provided, whereby a target protein fused to an intein - a protein splicing element - is selectively cleaved in a first step as depicted in Figure 1 with a thiol reagent, forming a carboxyl-terminal thioester of the target protein and releasing the target protein from the intein. In a subsequent step as shown in Figure 1, a desired, synthetic, protein or peptide having an amino-terminal cysteine is ligated to the target protein. Standard thiol-reagents such as DTT, or thiol-reagents optimized for ligation such as the odorless MESNA, may be used in the first step. The method permits the direct ligation of a desired peptide to a thioester bond that had linked a target protein to an intein. An in vivo variation of the method will permit production of a cytotoxic protein: a truncated, inactive, form of the protein fused to an intein is introduced in vivo, this fusion product is then selectively cleaved, and a synthetic protein or peptide is subsequently ligated at a carboxyl-terminal thioester of the target protein in order to restore the native activity of the cytotoxic protein.

MAILING ADDRESS OF SENDER (Please do not use customer number below): 7,001,745
Harriet M. Strimpel, D.Phil.
New England Biolabs, Inc.
240 County Road
Ipswich, MA 01938

PTO/SB/44 (04-05)
Approved for use through 04/30/2007. OMB 0651-0033
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

(Also Form PTO-1050)

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. :7,001,745

APPLICATION NO.: 09/786,009

ISSUE DATE :February 21, 2006

INVENTOR(S) : Ming-qun Xu, et al.

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

On title page, item 57 Abstract

replace

(57) **ABSTRACT**

The present invention provides methods that utilize compositions containing colostrinin, an constituent peptide thereof, an active analog thereof, and combinations thereof, as an oxidative stress regulator.

with

(57) Abstract: An in vitro method for producing a semi-synthetic fusion protein is provided, whereby a target protein fused to an intein - a protein splicing element - is selectively cleaved in a first step as depicted in Figure 1 with a thiol reagent, forming a carboxyl-terminal thioester of the target protein and releasing the target protein from the intein. In a subsequent step as shown in Figure 1, a desired, synthetic, protein or peptide having an amino-terminal cysteine is ligated to the target protein. Standard thiol-reagents such as DTT, or thiol-reagents optimized for ligation such as the odorless MESNA, may be used in the first step. The method permits the direct ligation of a desired peptide to a thioester bond that had linked a target protein to an intein. An in vivo variation of the method will permit production of a cytotoxic protein: a truncated, inactive, form of the protein fused to an intein is introduced in vivo, this fusion product is then selectively cleaved, and a synthetic protein or peptide is subsequently ligated at a carboxyl-terminal thioester of the target protein in order to restore the native activity of the cytotoxic protein.

MAILING ADDRESS OF SENDER (Please do not use customer number below): 7,001,745
Harriet M. Strimpel, D.Phil.
New England Biolabs, Inc.
240 County Road
Ipswich, MA 01938